Therefore, we further assessed the immune-memory effects of our combined tumour immunotherapy strategy (Fig. 8a) by rechallenging mice with the secondary inoculation of CT26-cancer cells on day 30, which was the 22nd day19,45 after SDT plus anti-PD-L1 treatment to remove the first tumour. Here, CD274 is linked to neoplasm.